Study start in the US and Europe confirmed for H2 2020

VIENNA, AUSTRIA / ACCESSWIRE / January 27, 2020 / AFFiRiS AG, a clinical-stage biopharmaceutical company developing novel disease-modifying specific active immunotherapies (SAITs) for patients with neurodegenerative diseases, today announced it had received feedback to its pre-Investigational New Drug ("IND") submission to the U.S. Food and Drug Administration ("FDA") regarding the planned Phase 2 clinical trial with AFFITOPE(R) PD01, the Company's lead candidate for the treatment of early-stage Parkinson's disease patients. As an outcome to the response, AFFiRiS will proceed with the preparations for the planned phase 2 study and confirms its intended initiation in the US and Europe in the second half of 2020.

The FDA has reviewed the pre-clinical data, the CMC-package, the clinical phase 1 study results and the phase 2 study plan of AFFITOPE(R) PD01. In its written response, the FDA addressed AFFiRiS' questions and provided guidance on the design of the planned phase 2 trial.

"We are pleased to have completed the pre-IND process, with the FDA providing helpful guidance for the continued advancement of AFFITOPE(R) PD01 for the treatment of Parkinson's disease, an indication with an urgent and significant unmet medical need," said Noel Barrett, Ph.D., AFFiRiS' Chief Executive Officer. "We appreciate the FDA's feedback as we endeavour to provide patients with a potentially disease-modifying immunotherapy utilizing our proprietary patented AFFITOME(R) technology."

About AFFITOPE(R) PD01:
AFFITOPE(R) PD01 is a synthetically produced alpha-synuclein (aSyn)-mimicking peptide based specific active immunotherapy (SAIT) that targets the protein aSyn, which plays a key role in the onset and progression of Parkinson's Disease. In a phase 1 study program, early Parkinson patients were observed for up to 48 months with regard to long-term safety, immunological and clinical parameters. The immunotherapy candidate was demonstrated to be well tolerated. AFFITOPE(R) PD01 induced a long lasting humoral immune response that could be reactivated upon booster application. Clinical scores for PD were stable during the entire study period in the PD01 treated group, however, the study was not designed and not powered to evaluate clinical efficacy. The phase 1 studies were supported by The Michael J. Fox Foundation for Parkinson's Research.

About Parkinson's disease:
Parkinson's disease (PD) is the second most common neurodegenerative disorder after Alzheimer's disease and the most common neurodegenerative movement disease. It affects approximately 1 % of the population above the age of 60, about 7-10 million people worldwide. PD is a chronic progressive disorder, defined by a combination of motoric and non-motoric syndromes. The hallmark of the disease is a substantial loss of dopaminergic neurons in the brain accompanied by accumulations of filamentous protein inclusions predominantly composed of alpha Synuclein (aSyn). Evidence suggests that the misfolding of the aSyn protein causes inflammation, synaptic dysfunction and finally neuronal cell death. Current therapies target symptoms but fail to modify the underlying neurodegeneration. In addition, these therapies result in varying degrees of side effects, and their beneficial effects are diminishing over time.

About AFFiRiS AG:
AFFiRiS is a clinical-stage biopharmaceutical company located in Vienna, Austria, that pursues the vision of using the immune system to find and fight human proteins central to the development and progression of neurodegenerative diseases, based on its proprietary patented AFFITOME(R) technology. The ultimate aim is to improve the lives of patients suffering from these diseases by providing disease-modifying specific active immunotherapies (SAIT). Besides its lead candidate AFFITOPE(R) PD01, AFFiRiS has programs against multiple system atrophy, Lewy body dementia, and chorea Huntington, which are in pre-clinical development. For further information, please visit www.affiris.com and follow us on LinkedIn.

About the Michael J. Fox Foundation for Parkinson's Research:
As the world's largest non-profit funder of Parkinson's research, The Michael J. Fox Foundation is dedicated to accelerating a cure for Parkinson's disease and improved therapies for those living with the condition today. The Foundation pursues its goals through an aggressively funded, highly targeted research program coupled with active global engagement of scientists, Parkinson's patients, business leaders, clinical trial participants, donors and volunteers. In addition to funding more than $800 million in research to date, the Foundation has fundamentally altered the trajectory of progress toward a cure. Operating at the hub of worldwide Parkinson's research, the Foundation forges ground-breaking collaborations with industry leaders, academic scientists and government research funders; increases the flow of participants into Parkinson's disease clinical trials with its online tool, Fox Trial Finder; promotes Parkinson's awareness through high-profile advocacy, events and outreach; and coordinates the grassroots involvement of thousands of Team Fox members around the world. Learn more at www.michaeljfox.org.

Contact AFFiRiS AG:
Dr. Cornelia Kutzer
E cornelia.kutzer@affiris.com
W http://www.affiris.com

Media contact:
MC Services AG
Julia Hofmann
P +49 89 210228 0
E affiris@mc-services.eu

SOURCE: AFFiRiS AG via EQS Newswire

ReleaseID: 574168

Investment will Advance Pioneering Whole Fungi Medicine Approach Which Focuses on Truffles

VANCOUVER, BC / ACCESSWIRE / January 27, 2020 / Codebase Ventures Inc. ("Codebase" or the "Company") (CSE:CODE)(FSE:C5B)(OTCQB:BKLLF), an investment company, announces that its wholly-owned subsidiary Titan Shrooms & Psychedelics Inc., has made its first investment in the Red Light Holland Corp., a company based in the Netherlands with a focus on the production, growth and sales of truffle based products in compliance with all applicable laws.

"We believe Codebase shareholders will benefit from Red Light Holland's unique approach with its focus on truffles and whole fungi medicine, moving away from synthetic alternatives," said Mr. Brian Keane, Director. "Titan's initial investment is the first step in building a portfolio to give our shareholders a front row seat to the mushrooms and psychedelics sector as it builds significant momentum. Titan's mandate is to leverage its deep relationships globally to offer the best exposure available at the forefront of this burgeoning sector, to the benefit of Codebase shareholders."

Red Light Holland Corp. Highlights:

Red Light Holland Corp. is strategically based in the Netherlands, a jurisdiction where selling truffles is legal
Red Light Holland Corp. believes in the entourage effect of ‘whole fungi' medicine and is designed to profit off of the entire truffle, including the proven psilocybin compound, to the highest degree
Red Light Holland is distinguishing itself from other clinically studied treatments that use a very expensive synthetic compound in an isolate state; and use none of the fungi entourage effects, which Red Light Holland believes are critical to the efficacy of the medicines that the company aims to produce.

Titan Shrooms & Psychedelics will focus on identifying investment opportunities that meet with Company's investment mandate. Building on its initial $50,000 debt facility with Red Light Holland provided on January 23, 2020, Codebase may invest up to $2 million in such opportunities going forward. CODE is an investment company and its investments focus upon new technologies or innovative and emerging industries that have the potential to provide shareholders with significant growth.

Titan Shrooms & Psychedelics is actively seeking investment opportunities at the forefront of the mushroom and micro-dosing psychedelic healthcare sector. Codebase is not averse to taking management positions as it relates to companies in which they are investing.

About Codebase Ventures Inc.

Codebase Ventures Inc. is an investment company, led by technology and business experts who invest early in great ideas in sectors that have significant upside, including the cannabis sector. We operate from the understanding that technology is always evolving, bringing early opportunities for strategic investments that can deliver the exponential returns to our shareholders. We seek out and empower the innovators who are building tomorrow's standards with platforms, protocols and innovations – not just products. We invest early, support our founders, take their ideas to market and work tirelessly to help them realize their vision.

Neither the Canadian Securities Exchange nor its Regulation Services Provider (as that term is defined in the policies of the Canadian Securities Exchange) accepts responsibility for the adequacy or accuracy of this release.

For further information, please contact:

Brian Keane, Director

Investor Relations

Telephone: 1 (778) 806-5150

E-mail: IR@codebase.ventures

Forward Looking Statements

Certain information set forth in this news release may contain forward-looking statements that involve substantial known and unknown risks and uncertainties. All statements other than statements of historical fact are forward-looking statements, including, without limitation, statements regarding future financial position, business strategy, use of proceeds, corporate vision, proposed acquisitions, partnerships, joint-ventures and strategic alliances and co-operations, budgets, cost and plans and objectives of or involving the Company. Such forward-looking information reflects management's current beliefs and is based on information currently available to management. Often, but not always, forward-looking statements can be identified by the use of words such as "plans", "expects", "is expected", "budget", "scheduled", "estimates", "forecasts", "predicts", "intends", "targets", "aims", "anticipates" or "believes" or variations (including negative variations) of such words and phrases or may be identified by statements to the effect that certain actions "may", "could", "should", "would", "might" or "will" be taken, occur or be achieved. A number of known and unknown risks, uncertainties and other factors may cause the actual results or performance to materially differ from any future results or performance expressed or implied by the forward-looking information. These forward-looking statements are subject to numerous risks and uncertainties, certain of which are beyond the control of the Company including, but not limited to, the impact of general economic conditions, industry conditions and dependence upon regulatory approvals. Readers are cautioned that the assumptions used in the preparation of such information, although considered reasonable at the time of preparation, may prove to be imprecise and, as such, undue reliance should not be placed on forward-looking statements. The Company does not assume any obligation to update or revise its forward-looking statements, whether as a result of new information, future events, or otherwise, except as required by securities laws.

SOURCE: Codebase Ventures Inc.

ReleaseID: 574096

First month results put wknd! branded products in 35 stores selling over 2000 units

VANCOUVER, BC / ACCESSWIRE / January 27, 2020 / Weekend Unlimited Inc. ("Weekend" or the "Company") (CSE:POT)(FSE:0OS1)(OTCQB:WKULF) a lifestyle cannabis company, is providing an update on its launch into the Oklahoma market as the Company sees strong results in the first month of operations.

Oklahoma Highlights:

WKND! Branded Products now available in 35 stores
2020 units of WKND! Branded Products sold since mid-December
12 re-orders of WKND! Branded Products indicating sell through of initial shipment
Due to success of WKND! branded products the Company is expanding WKND! SKUs
In addition, as a result of the success of WKND! Branded products, the Company will accelerate its launch of Orchard Heights branded products, with a target to have them in the market by the end of Q1

"With approximately 1500 retail stores in operation in the State of Oklahoma, in the first month the sales team has made pitches to approximately 15% of the market and delivered tremendous results, adhering to our mandate to have profitable operations," said Mr. Chris Backus, Weekend President and CEO. "We are targeting pitches to 300 new stores in the next month as the response to the brand has been outstanding. Our partners in Oklahoma, Ruby Mae's, are absolutely terrific and delivering on all our shared targets boding well for growth and future expansion."

"The market has fully embraced the WKND! brand and our relationships on the ground are really excited as we build a strong retail presence, growing the line with our Ruby Mae's portfolio," said Mr. Travis Hunter, Ruby Mae's CEO. "We are paving the way to a dominant market share overall, and the addition of the Orchard Heights branded product line is being met with great enthusiasm from buyers."

The Oklahoma medical marijuana industry has become one of the largest and most valuable in the USA, the market has exceeded predications with over 200,000 medical cannabis patients registered, equal to 5% of the state's 4,000,000 population and over $350 million in sales in the first year.1 Compare that to Florida with 21,000,000 residents, with only 300,000 registered medical marijuana users equaling 1.4% of the population2 and it is evident that Weekend's strategy to be an early mover in Oklahoma is delivering results.

"We know we have fantastic brands, that has been proven out with the response from partners and retailers, the key now is to continue advancing our strategy to grow brand awareness with consumers, build sustainable and profitable relationships and build off of each success by launching in up and coming states like Oklahoma, where there is opportunity to have a strong. profitable market presence for our brands," added Mr. Backus.

1 https://mjbizdaily.com/oklahoma-medical-marijuana-industry-on-pace-to-hit-350-million/

2 https://www.fool.com/investing/2019/12/04/for-cannabis-oklahomas-more-than-ok.aspx

For further information, please contact:

Mr. Chris Backus, President & CEO, Director

Telephone: 1(236) 317-2812

E-mail: IR@weekendunlimited.com

About Weekend Unlimited Inc.

Weekend Unlimited is a lifestyle-based recreational cannabis company. The Company is developing premium products designed to deliver life's highs, anytime, anywhere. With a presence in both the U.S. and Canada, Weekend Unlimited is well-positioned to launch and scale the brands that will define recreational cannabis. Learn more at www.weekendunlimited.com.

Neither the Canadian Securities Exchange nor its Regulation Services Provider (as that term is defined in the policies of the Canadian Securities Exchange) accepts responsibility for the adequacy or accuracy of this release.

Forward Looking Statements

Certain information set forth in this news release may contain forward-looking statements that involve substantial known and unknown risks and uncertainties. All statements other than statements of historical fact are forward-looking statements, including, without limitation, statements regarding future financial position, business strategy, use of proceeds, corporate vision, proposed acquisitions, partnerships, joint-ventures and strategic alliances and co-operations, budgets, cost and plans and objectives of or involving the Company. Such forward-looking information reflects management's current beliefs and is based on information currently available to management. Often, but not always, forward-looking statements can be identified by the use of words such as "plans", "expects", "is expected", "budget", "scheduled", "estimates", "forecasts", "predicts", "intends", "targets", "aims", "anticipates" or "believes" or variations (including negative variations) of such words and phrases or may be identified by statements to the effect that certain actions "may", "could", "should", "would", "might" or "will" be taken, occur or be achieved. A number of known and unknown risks, uncertainties and other factors may cause the actual results or performance to materially differ from any future results or performance expressed or implied by the forward-looking information. These forward-looking statements are subject to numerous risks and uncertainties, certain of which are beyond the control of the Company including, but not limited to, the impact of general economic conditions, industry conditions and dependence upon regulatory approvals. Readers are cautioned that the assumptions used in the preparation of such information, although considered reasonable at the time of preparation, may prove to be imprecise and, as such, undue reliance should not be placed on forward-looking statements. The Company does not assume any obligation to update or revise its forward-looking statements, whether as a result of new information, future events, or otherwise, except as required by securities laws.

SOURCE: Weekend Unlimited Inc.

ReleaseID: 574161

SAN FRANCISCO, CA / ACCESSWIRE / January 27, 2020 / Hagens Berman has filed a class action Complaint on behalf of investors in HEXO Corp. (NYSE:HEXO). The firm alerts HEXO investors of today's deadline to move for lead plaintiff in a securities fraud class action pending against the Company and urges HEXO investors who have suffered losses to contact the firm immediately.

Class Period: Jan. 25, 2019 – Nov. 15, 2019
Lead Plaintiff Deadline: Jan. 27, 2020
Sign Up Now: www.hbsslaw.com/investor-fraud/HEXO
Contact An Attorney Immediately: HEXO@hbsslaw.com
844-916-0895

Hagens Berman's HEXO Securities Class Action:

According to the detailed Complaint filed by Hagens Berman, Defendants failed to disclose to investors that: (1) HEXO's reported inventory was misstated due to its failure to write down or write off obsolete product; (2) HEXO was engaging in channel-stuffing to inflate its revenue figures; and (3) HEXO was cultivating unlicensed cannabis at its facilities.

The truth emerged through a series of disclosures occurring between Oct. 4, 2019 and Nov. 15, 2019, when the Company announced it was producing cannabis in a section of its Niagara facility that was not properly licensed with Health Canada.

As a result of these disclosures, the value of HEXO stock has consistently decreased, damaging investors.

On Jan. 2, 2020, the Company restated its FY-2019 annual financial statements and Q-1 FY 2020 interim financial statements. Notably, the Company increased its annual impairment loss on inventory by about 14% and disclosed material weaknesses in internal controls over financial reporting.

On Jan. 17, 2020, the Company's questionable accounting practices came into focus again, when MarketWatch published a report challenging the Company's employee-options accounting. MarketWatch reported that since June 2017, the Company has been incorrectly tabulating the remaining lifetime weighted average of its employee stock options, potentially violating International Financial Reporting Standards.

"We're focused on investors' losses and proving Defendants knowingly provided false financial information to the market," said Reed Kathrein, the Hagens Berman partner leading the investigation.

If you purchased HEXO common stock during the Class Period and suffered significant losses, click here to discuss your legal rights with Hagens Berman.

Whistleblowers: Persons with non-public information regarding HEXO should consider their options to help in the investigation or take advantage of the SEC Whistleblower program. Under the new program, whistleblowers who provide original information may receive rewards totaling up to 30 percent of any successful recovery made by the SEC. For more information, call Reed Kathrein at 844-916-0895 or email HEXO@hbsslaw.com.

About Hagens Berman

Hagens Berman is a national law firm with nine offices in eight cities around the country and eighty attorneys. The firm represents investors, whistleblowers, workers and consumers in complex litigation. More about the firm and its successes is located at hbsslaw.com. For the latest news visit our newsroom or follow us on Twitter at @classactionlaw.

Contact:

Reed Kathrein, 844-916-0895

SOURCE: Hagens Berman Sobol Shapiro LLP

ReleaseID: 574084

KUTZTOWN, PA / ACCESSWIRE / January 27, 2020 / With a strong vision to succeed and aid others in their pathway to success, Androw Narouz is a 21-year-old born in Alexandria, Egypt. Initially, He was enduring his College course in Pennsylvania whilst also amassing a large student debt. He didn't feel comfortable with the accumulated debt, knowing that as it stands, he would be paying this off for the rest of his life. This, of course, sounded bleak to Androw, who knew there was a lot more to life than switching between minimum wage work simply to survive. After having his eyes opened to the potential to earn trading on the Foreign Exchange market, He was mentally invested.

Early Experience
After learning how to trade and transforming $2,000 into $80,000 (which was enough to comfortably pay off his college tuition fees), he became infatuated with the industry and wanted to provide more for the community. Due to this, he teamed up with a partner to start a company (that won't be named) which sold forex signals for $100 a month. Androw was responsible for providing profitable signals to the community, while his partner dealt with the marketing side. This allowed him to educate on the topic and truly benefit the lives of his customers, all whilst unpaid due to payment issues on behalf of his partner. Unfortunately, this came to an end when he worked for three months with no pay and woke up to notice he had been locked out of the community and blocked from all social media, meanwhile his partner was jetting off to Costa Rica with all of his money, $30,000 to be precise. This left Androw with little but $100 to his name, however, he is not one to dig his head in the Costa Rican sand similar to his ex-partner. This only spurred his on to embark on a journey of his own- create a revolutionary interface that would allow individuals to become independent in trading the financial markets.

A New Beginning
What he realized, and what many people in the industry also realize, is that there is a severe lack of legitimacy. Varying from courses that simply regurgitate free online information, to signal providers who are professional and supportive until they have your money- at which point they feel they no longer need to provide quality educational information. There was a clear gap in the market here- which was recognized by Androw, as he established Forex Blade LLC in 2017. This company was designed from the beginning to employ credibility and trust back into the currently skeptical industry that is forex. Through fifteen-hour days, severe concentration and dedication, Forex Blade LLC has been able to offer a unique product that genuinely benefits all of its members and is now playing a completely different ball game to all competitors.

Artificial Intelligence Takes on Forex
It all began with an expert advisor (EA) that he created which customers connected to their account and simply sat back to reap the profits. The EA would trade 24/5, allowing for no stress weekends that everyone desires deep down. The safest method allowed for returns of 5-20% monthly, which is considerably more than any offer of interest attainable from a bank. This is the recommended setting however for higher gains there are two other modes. After receiving the five-star feedback from his services, He felt inspired, but he also felt like his skills and knowledge base could allow him to provide a lot more for his community. Being a firm believer in "What you give, is what you get", he began two projects which would completely transform his students from novices to elite traders. The first project was an upgraded version of the automated EA. Over a 3-year period, He created an expert advisor which runs using Artificial Intelligence. It was extremely difficult for him to acquire a programmer who had the expertise and elegance to make his vision come true, due to its complexity. As the A.I was making progress on its completion, he began the most important project in his opinion, which is Forex Blade University.

Building an Empire
ForexBlade University was released in late 2019 and boasts an extensive selection of educational videos, quizzes, and PDFs. The course begins with a short introduction before moving on to the beginner level which includes everything you need to know before taking the leap into the Forex Market, followed by a short quiz. After familiarizing yourself with the FX market, you would then be fully equipped to enter the intermediate level, which would educate you all about the most important things you should know when opening an account with a broker, ranging from important considerations which will ensure your money's safety, to exactly how to deposit your money into the account. Throughout each video, Androw portrayed an exceptional way of condensing each segment of information into an easy to understand format. Expert level, where things get really exciting, is no different in its quality and depth, yet also simplicity. This section begins with a rundown on the mentality required to function at an expert level, an exceptionally important component when attempting to achieve consistency in such a volatile market. Following this, all of the necessary and advanced methods of chart work are lectured in a unique fashion.

How To Get Started Trading Forex in 2020?
The course is rife with expert information, to seriously put you ahead of all other retail traders. Examples of this would be the best-selling Forex books and even a comprehensive selection of videos that display just how profitable the given strategy is. Not to mention the "Become a Millionaire" section which is too valuable and exclusive to speak of here. This is where it's at. You will not learn the content of this quality anywhere else, and definitely not for the price which is being asked. As well as all of the aforementioned content, after purchase, you will be added to a private Discord chat channel. This is exclusive and it cannot be glossed over how beneficial this is to growth. Being in an exclusive channel with other people of varying abilities, however all on the same journey really does promote reflection, and ultimately growth. It's going to be extremely interesting watching such a young man absolutely transform the Forex Industry and help all of his students in 2020.

Contact Details
Name: Androw Narouz
Company Name: Forex Blade LLC
Email: Customerservice@forex-blade.com
website: https://www.forex-blade.com/

SOURCE: Forex Blade LLC

ReleaseID: 574166